OFFERING A FAST, EFFICIENT AND COST EFFECTIVE SERVICE FOR PAEDIATRIC CLINICAL TRIALS IN RARE GENETIC DISORDERS THE COMPANY Myriad Trials is currently engaged in several high-impact clinical research studies and strategic initiatives across multiple locations.Ongoing Clinical Trials & StudiesMyriad is actively running two significant clinical trials at The Portland Hospital site: Hypochondroplasia Studies: We are involved in two natural history studies focused on children with Hypochondroplasia: The Natural History Study (BMN111-902), sponsored by BioMarin. The ACCEL natural history study, sponsored by QED Therapeutics. We have established a new site for intervention studies at the Allergy Centre of Excellence – ACE: Allergy and Growth studies: We have set up two intervention studies at this Central London site: The DBV Therapeutics COMFORT study for the treatment of peanut allergy in infants. The Lumos OraGrowth study for children with growth hormone deficiency Recruitment and Global PresenceWe are actively recruiting participants for our ongoing studies and will be presenting at the American College of Medical Genetics in Baltimore in March 2026, highlighting our commitment to contributing to the global genetics and rare disease research community. MELITA IRVING Myriad Trials is the brainchild of Melita Irving, a highly respected Clinical Geneticist with an impressive 24 years of experience. Her career, which began with paediatric training and culminated in the prestigious FRCPCH qualification, has been marked by numerous successful initiatives. Melita is a Fellow of the Royal College of Paediatrics and Child Health and has collaborated with renowned organizations such as BioMarin, QED/BridgeBio, and Ascendis, further solidifying her credibility and expertise in the field. Previously, Melita was a former President of the Medical Genetics section of the Royal Society of Medicine.
